Boehringer Ingelheim's attempt to develop the first drug therapy for impaired cognitive function in schizophrenia, a core feature of the illness, has suffered what looks like a terminal setback.

The FDA has started a priority review of Boehringer Ingelheim's small-molecule HER2 inhibitor zongertinib as a treatment for a form of lung cancer, setting up a decision later this year and giving ...

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

“If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,” said Frank Hübler, Member of the Board of Managing Directors with responsibility ...

Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net salesCompany prepares ...